4.6 Article

Etanercept: An overview

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 49, Issue 2, Pages S105-S111

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/mjd.2003.554

Keywords

-

Categories

Ask authors/readers for more resources

Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available